公开(公告)号：US20230257373A1

公开(公告)日：2023-08-17

申请号：US18041241

申请日：2021-08-13

Applicant: The Trustees of Indiana University

Inventor： Julia Catherine Van Kessel Bochman ,  Laura Caroline Brown

IPC: C07D417/04 ,  C07D405/14 ,  C07D409/12 ,  C07D409/06 ,  C07D405/06 ,  C07D233/84 ,  C07D333/34

CPC classification number: C07D417/04 ,  C07D405/14 ,  C07D409/12 ,  C07D409/06 ,  C07D405/06 ,  C07D233/84 ,  C07D333/34

Abstract: Inhibition of quorum sensing in Gram-negative bacteria, particularly strains of Vibrio, by certain compounds is disclosed. Compositions to treat bacterial infections and methods to treat such infections are also provided.

公开(公告)号：US20230250078A1

公开(公告)日：2023-08-10

申请号：US17941854

申请日：2022-09-09

Applicant: SERVIER PHARMACEUTICALS LLC

Inventor： Giovanni Cianchetta ,  Byron DeLaBarre ,  Janeta Popovici-Muller ,  Francesco G. Salituro ,  Jeffrey O. Saunders ,  Jeremy Travins ,  Shunqi Yan ,  Tao Guo ,  Li Zhang

IPC: C07D401/14 ,  A61K31/5377 ,  C07D251/18 ,  A61K31/53 ,  C07D401/12 ,  C07D413/14 ,  C07D405/14 ,  C07D403/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D493/08

CPC classification number: C07D401/14 ,  A61K31/5377 ,  C07D251/18 ,  A61K31/53 ,  C07D401/12 ,  C07D413/14 ,  C07D405/14 ,  C07D403/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D493/08

Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

公开(公告)号：US20230250070A1

公开(公告)日：2023-08-10

申请号：US18010032

申请日：2021-06-18

Applicant: AC IMMUNE SA

Inventor： Emanuele GABELLIERI ,  Jérôme MOLETTE ,  Véronique DEHLINGER

IPC: C07D263/28 ,  C07D413/04 ,  C07D417/04 ,  C07D233/58 ,  C07D213/64 ,  C07D213/55 ,  C07C335/16 ,  C07D309/06 ,  C07D261/08

CPC classification number: C07D263/28 ,  C07C335/16 ,  C07D213/55 ,  C07D213/64 ,  C07D233/58 ,  C07D261/08 ,  C07D309/06 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of the NLRP3 inflammasome pathway. In particular, the component of the inflammasome pathway is a NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome. More particularly, the compounds of the present invention have the capability to modulate the NLRP3 inflammasome pathway. Further, the compounds of the present invention are suitable for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation, in particular decrease, IL-1 beta and/or IL-18 levels.

公开(公告)号：US20230242543A1

公开(公告)日：2023-08-03

申请号：US18295394

申请日：2023-04-04

Applicant: Prelude Therapeutics Incorporated

Inventor： Liang Lu ,  Rupa Shetty ,  Andrew Paul Combs ,  Chaofeng Dai ,  Raul Andrew Leal ,  Klare Lazor Bersch

IPC: C07D487/04 ,  C07D401/08 ,  C07D417/14 ,  C07D471/04 ,  C07D401/14 ,  C07D417/08 ,  C07D413/14 ,  A61P35/00 ,  C07D401/04 ,  C07D405/14 ,  C07D417/04 ,  C07D498/04

CPC classification number: C07D487/04 ,  C07D401/08 ,  C07D417/14 ,  C07D471/04 ,  C07D401/14 ,  C07D417/08 ,  C07D413/14 ,  A61P35/00 ,  C07D401/04 ,  C07D405/14 ,  C07D417/04 ,  C07D498/04

Abstract: The disclosure is directed to, in part, to CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.

公开(公告)号：US20230242512A1

公开(公告)日：2023-08-03

申请号：US17984065

申请日：2022-11-09

Applicant: Valo Health, Inc.

Inventor： Xiaozhang Zheng ,  Matthew W. Martin ,  Pui Yee Ng ,  Jennifer R. Thomason ,  Bingsong Han ,  Aleksandra Rudnitskaya ,  David R. Lancia, JR.

IPC: C07D403/04 ,  C07D209/10 ,  C07D209/44 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

CPC classification number: C07D403/04 ,  C07D209/10 ,  C07D209/44 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula:




wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.

公开(公告)号：US20230234958A1

公开(公告)日：2023-07-27

申请号：US18066551

申请日：2022-12-15

Applicant: Relay Therapeutics, Inc. ,  D. E. Shaw Research, LLC.

Inventor： Alexander M. Taylor ,  Andre Lescarbbeau ,  Elizabeth H. Kelley ,  Kelley C. Shortsleeves ,  W. Patrick Walters ,  Mark Andrew Murcko ,  Thomas H. McLean ,  Hakan Gunaydin ,  Fabrizio Giordanetto ,  Eric Therrien

IPC: C07D487/04 ,  C07D401/04 ,  C07D401/14 ,  C07D519/00 ,  C07D221/20 ,  C07D401/12 ,  C07D417/04 ,  C07D417/14 ,  C07D491/107 ,  C07D513/04

CPC classification number: C07D487/04 ,  C07D401/04 ,  C07D401/14 ,  C07D519/00 ,  C07D221/20 ,  C07D401/12 ,  C07D417/04 ,  C07D417/14 ,  C07D491/107 ,  C07D513/04

Abstract: The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.

公开(公告)号：US20230234935A1

公开(公告)日：2023-07-27

申请号：US18003088

申请日：2021-06-25

Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Inventor： Robert J. DEVITA ,  Chalada SUEBSUWONG ,  Kunal KUMAR ,  Roberto J. SANCHEZ ,  Andrew F. STEWART ,  Peng WANG ,  Michael B. LAZARUS

IPC: C07D401/04 ,  C07D471/04 ,  C07D403/04 ,  C07D213/74 ,  C07D403/12 ,  C07D403/14 ,  C07D401/14 ,  C07D487/04 ,  C07D417/04 ,  C07F5/02 ,  C07D413/12 ,  C07D413/10 ,  A61K45/06

CPC classification number: C07D401/04 ,  C07D471/04 ,  C07D403/04 ,  C07D213/74 ,  C07D403/12 ,  C07D403/14 ,  C07D401/14 ,  C07D487/04 ,  C07D417/04 ,  C07F5/025 ,  C07D413/12 ,  C07D413/10 ,  A61K45/06

Abstract: Disclosed herein are kinase inhibitor compounds having the structure (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, L, Q, and Y are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

公开(公告)号：US20230233516A1

公开(公告)日：2023-07-27

申请号：US18147171

申请日：2022-12-28

Applicant: TECHFIELDS PHARMA CO., LTD

Inventor： Chongxi Yu

IPC: A61K31/352 ,  C07D215/18 ,  A61K47/54 ,  C07D209/42 ,  C07D295/088 ,  C07D211/34 ,  C07D231/14 ,  C07D313/14 ,  C07D417/04 ,  C07D491/048 ,  C07D501/22 ,  C07D277/56 ,  C07D207/34 ,  A61K8/31 ,  A61K31/015 ,  C07C15/30 ,  C07C15/38

CPC classification number: A61K31/352 ,  C07D215/18 ,  A61K47/54 ,  C07D209/42 ,  C07D295/088 ,  C07D211/34 ,  C07D231/14 ,  C07D313/14 ,  C07D417/04 ,  C07D491/048 ,  C07D501/22 ,  C07D277/56 ,  C07D207/34 ,  A61K8/31 ,  A61K31/015 ,  C07C15/30 ,  C07C15/38 ,  Y02A50/30

Abstract: The invention provides compositions or pharmaceutical compositions of novel high penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. For example, HPCs of NSAIA have demonstrated indications such as treating hair loss and bold. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

公开(公告)号：US11684610B2

公开(公告)日：2023-06-27

申请号：US17045882

申请日：2019-04-04

Applicant: YUNGJIN PHARM. CO., LTD.

Inventor： Ki Ryang Kweon ,  Jun Young Heo ,  Min Ho Shong ,  Jeong Su Han ,  Min Jeong Ryu

IPC: A61K31/4184 ,  A61P35/02 ,  A61P35/00 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4745 ,  C07D263/60 ,  C07D401/04 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04

CPC classification number: A61K31/4184 ,  A61K31/4192 ,  A61K31/423 ,  A61K31/428 ,  A61K31/4745 ,  A61P35/00 ,  A61P35/02 ,  C07D263/60 ,  C07D401/04 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of solid cancers or blood cancers such as acute leukemia or chronic leukemia, including, as an active ingredient, a 1,2-naphthoquinone derivative compound or a pharmaceutically acceptable salt thereof, wherein the 1,2-naphthoquinone derivative compound has excellent effects in killing cancer cells of various solid cancers, acute leukemia, and chronic leukemia, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of cancer, in particular, solid cancers, acute leukemia, or chronic leukemia.

公开(公告)号：US20230192626A1

公开(公告)日：2023-06-22

申请号：US17999408

申请日：2021-05-26

Applicant: Baylor College of Medicine

Inventor： Jin Wang ,  Hui Zheng ,  Lisheng Deng ,  Anamitra Ghosh

IPC: C07D235/18 ,  C07D235/14 ,  C07D235/30 ,  C07D235/26 ,  C07D235/20 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D413/10 ,  C07D401/10 ,  C07D403/10 ,  C07D401/12 ,  C07D403/12 ,  C07D487/04 ,  C07D413/12 ,  C07D471/04 ,  C07D473/40 ,  C07D473/34 ,  A61K45/06

CPC classification number: C07D235/18 ,  C07D235/14 ,  C07D235/30 ,  C07D235/26 ,  C07D235/20 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D417/04 ,  C07D413/10 ,  C07D401/10 ,  C07D403/10 ,  C07D401/12 ,  C07D403/12 ,  C07D487/04 ,  C07D413/12 ,  C07D471/04 ,  C07D473/40 ,  C07D473/34 ,  A61K45/06

Abstract: Novel soluble epoxide hydrolase (sEH) inhibitors are provided, along with methods for their use. The soluble epoxide hydrolase inhibitors are useful in treating and/or preventing sEH-related related diseases, such as Alzheimer's disease and inflammation. Also provided are methods for inhibiting soluble epoxide hydrolase in a cell using the compounds and compositions described herein.